Harrow, Inc. (HROW) shareholders
Close on Nov 16, 2026Market cap $1.09BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Mark L. Baum | 4,056,962 | 10.69% | 13D (active) amendment | Apr 3, 2025 |
| Private Capital Management, LLC ( ) | 3,630,496 | 10.34% | 13G (passive) | Dec 31, 2023 |
| BlackRock, Inc. | 2,757,783 | 7.40% | 13G (passive) amendment | Sep 30, 2026 |
| Opaleye, L.P. Joint filing with Opaleye Management Inc. (6.44%), James Silverman (6.44%) | 2,400,000 | 6.44% | 13G (passive) amendment | Jun 30, 2026 |
| James Silverman Joint filing with Opaleye Management Inc. (5.62%), Opaleye, L.P. (5.62%) | 2,105,000 | 5.62% | 13G (passive) amendment | Sep 30, 2026 |
| Daniel Kaufman | 1,878,000 | 5.04% | 13G (passive) | Mar 10, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of HROW | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 2,740,117 | 7.31% | $116.37M | +187,358 | 0.00% |
| Opaleye Management Inc. | 2,400,000 | 6.40% | $101.93M | −432,230 | 9.23% |
| Private Capital Management, LLC | 1,598,770 | 4.26% | $67.90M | +36,770 | 5.98% |
| Vanguard Capital Management LLC | 1,417,212 | 3.78% | $60.19M | +14,156 | 0.00% |
| Deep Track Capital, LP | 969,000 | 2.58% | $41.15M | New | 0.60% |
| State Street Corp | 939,888 | 2.51% | $39.92M | +84,841 | 0.00% |
| Geode Capital Management, LLC | 905,560 | 2.42% | $38.47M | +53,526 | 0.00% |
| Bamco Inc /Ny/ | 809,350 | 2.16% | $34.37M | New | 0.05% |
| Dimensional Fund Advisors LP | 667,036 | 1.78% | $28.33M | +87,516 | 0.01% |
| Jupiter Topco LLC | 579,127 | 1.54% | $24.60M | New | 0.01% |
| Divisadero Street Capital Management, LP | 439,155 | 1.17% | $18.65M | New | 0.42% |
| Rice Hall James & Associates, LLC | 387,545 | 1.03% | $16.46M | +19,368 | 0.80% |
| Marshall Wace, Llp | 369,435 | 0.99% | $15.69M | −275,483 | 0.01% |
| Citadel Advisors LLC | 359,874 | 0.96% | $15.28M | +138,616 | 0.00% |
| Northern Trust Corp | 323,206 | 0.86% | $13.73M | +26,341 | 0.00% |
| Schonfeld Strategic Advisors LLC | 319,625 | 0.85% | $13.57M | New | 0.05% |
| Vanguard Portfolio Management LLC | 318,610 | 0.85% | $13.53M | +29,735 | 0.00% |
| Charles Schwab Investment Management Inc | 273,696 | 0.73% | $11.62M | +3,160 | 0.00% |
| Vanguard Fiduciary Trust Co | 235,418 | 0.63% | $10.00M | +7,797 | 0.00% |
| Westside Investment Management, Inc. | 224,051 | 0.60% | $9.52M | +38,125 | 1.25% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 223 | 22M | 57.4% | 41 / 81 | 65 / 34 | 5M | 5M |
| Q1 2026 | 219 | 21M | 57.3% | 44 / 67 | 77 / 33 | 5M | 3M |
| Q4 2025 | 215 | 22M | 59.3% | 49 / 65 | 66 / 30 | 3M | 2M |
| Q3 2025 | 197 | 21M | 56.9% | 56 / 53 | 60 / 18 | 3M | 3M |
| Q2 2025 | 160 | 21M | 56.2% | 29 / 65 | 43 / 25 | 2M | 2M |
| Q1 2025 | 156 | 21M | 56.3% | 23 / 51 | 59 / 30 | 3M | 2M |
| Q4 2024 | 165 | 21M | 55.8% | 38 / 52 | 52 / 31 | 2M | 3M |
| Q3 2024 | 159 | 21M | 56.6% | 60 / 39 | 42 / 9 | 7M | 3M |
| Q2 2024 | 110 | 19M | 51.3% | 21 / 42 | 30 / 22 | 2M | 5M |
| Q1 2024 | 112 | 23M | 60.8% | 15 / 38 | 38 / 15 | 2M | 3M |
| Q4 2023 | 113 | 24M | 65.3% | 13 / 41 | 36 / 26 | 4M | 5M |
| Q3 2023 | 128 | 25M | 66.8% | 24 / 52 | 29 / 8 | 5M | 3M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
158 funds held HROW in Q2 2026, 55% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of HROW | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,001,445 | 2.67% | $42.53M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 842,000 | 2.25% | $35.76M | 0.04% | Jun 30, 2026 |
| Baron Discovery Fund | 576,069 | 1.54% | $24.47M | 1.34% | Jun 30, 2026 |
| Janus Henderson Venture Fund | 468,451 | 1.25% | $19.90M | 0.55% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 383,781 | 1.02% | $16.30M | 0.02% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 353,740 | 0.94% | $13.71M | 0.04% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 298,900 | 0.80% | $12.69M | 0.08% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF | 182,110 | 0.49% | $7.73M | 1.81% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 170,863 | 0.46% | $6.02M | 0.01% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 161,996 | 0.43% | $5.70M | 0.03% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 158,672 | 0.42% | $5.59M | 0.02% | May 31, 2026 |
| U.S. Small Cap Portfolio | 148,359 | 0.40% | $5.75M | 0.03% | Jul 31, 2026 |
| Private Capital Management Value Fund | 126,154 | 0.34% | $4.89M | 6.73% | Jul 31, 2026 |
| Dimensional U.S. Small Cap ETF | 125,599 | 0.34% | $4.87M | 0.03% | Jul 31, 2026 |
| JNL Multi-Manager Small Cap Growth Fund | 120,054 | 0.32% | $5.10M | 0.20% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Mark L. Baum | CHIEF EXECUTIVE OFFICER, Director | 3,594,256 | 9.59% | May 15, 2026 |
| Amir Shojaei | CHIEF SCIENTIFIC OFFICER | 0 | – | Aug 17, 2026 |
| Andrew R. Boll | PRESIDENT AND CFO | 814,679 | 2.17% | May 15, 2026 |
| Patrick William Sullivan | CHIEF COMMERCIAL OFFICER | – | – | Feb 2, 2026 |
| Francis William Mullery Jr | CEO, ImprimisRx | – | – | Oct 10, 2025 |
| Randall E. Pollard | CHIEF ACCOUNTING OFFICER | – | – | Sep 9, 2025 |
| John P. Saharek | CEO & President, ImprimisRx | 467,388 | 1.25% | Apr 7, 2025 |
| Lauren P. Silvernail | Director | 1,000 | 0.00% | Jun 22, 2026 |
| Perry J. Sternberg | Director | – | – | Jun 22, 2026 |
| Adrienne L. Graves | Director | 1,000 | 0.00% | Jun 22, 2026 |
| Management Inc. Opaleye | 10% owner | 3,681,428 | 9.82% | Mar 5, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Amir Shojaei CHIEF SCIENTIFIC OFFICER | Aug 14, 2026 | Sale | −11,250 | $40.00 | $450.00K | 0 |
| Amir Shojaei CHIEF SCIENTIFIC OFFICER | Aug 14, 2026 | Option exercise | +11,250 | $35.96 | $404.55K | 11,250 |
| Adrienne L. Graves Director | May 18, 2026 | Buy | +1,000 | $31.07 | $31.07K | 1,000 |
| Lauren P. Silvernail Director | May 18, 2026 | Buy | +1,000 | $31.00 | $31.00K | 1,000 |
| Andrew R. Boll PRESIDENT AND CFO | May 14, 2026 | Buy | +3,500 | $29.90 | $104.65K | 814,679 |
| Mark L. Baum CHIEF EXECUTIVE OFFICER, Director | May 14, 2026 | Buy | +10,000 | $30.20 | $302.00K | 2,996,130 |
| Management Inc. Opaleye 10% owner | Mar 4, 2026 | Sale | −4,263 | $39.67 | $169.11K | 59,428 |
| Management Inc. Opaleye 10% owner | Mar 4, 2026 | Sale | −134,000 | $39.67 | $5.32M | 3,622,000 |
| Management Inc. Opaleye 10% owner | Mar 3, 2026 | Sale | −59,000 | $39.15 | $2.31M | 3,756,000 |
| Management Inc. Opaleye 10% owner | Mar 3, 2026 | Sale | −1,309 | $39.15 | $51.25K | 63,691 |
| Management Inc. Opaleye 10% owner | Feb 27, 2026 | Sale | −5,000 | $54.18 | $270.90K | 65,000 |
| Management Inc. Opaleye 10% owner | Jan 6, 2026 | Sale | −20,000 | $53.35 | $1.07M | 70,000 |
| Mark L. Baum CHIEF EXECUTIVE OFFICER, Director | Dec 12, 2025 | Option exercise | +180,000 | $3.95 | $711.00K | 3,066,124 |
| Mark L. Baum CHIEF EXECUTIVE OFFICER, Director | Dec 12, 2025 | Tax withholding | −79,994 | $47.06 | $3.76M | 2,986,130 |
| Andrew R. Boll PRESIDENT AND CFO | Dec 12, 2025 | Tax withholding | −26,665 | $47.06 | $1.25M | 811,179 |
| Andrew R. Boll PRESIDENT AND CFO | Dec 12, 2025 | Option exercise | +60,000 | $3.95 | $237.00K | 837,844 |
| Mark L. Baum CHIEF EXECUTIVE OFFICER, Director, 10% owner | Jul 21, 2025 | Option exercise | +600,000 | $7.87 | $4.72M | 3,199,462 |
| Mark L. Baum CHIEF EXECUTIVE OFFICER, Director, 10% owner | Jul 21, 2025 | Tax withholding | −313,338 | $37.08 | $11.62M | 2,886,124 |
| Management Inc. Opaleye 10% owner | Jun 10, 2025 | Sale | −15,000 | $30.80 | $462.00K | 90,000 |
| Management Inc. Opaleye 10% owner | Jun 9, 2025 | Sale | −15,204 | $30.37 | $461.75K | 105,000 |
| Management Inc. Opaleye 10% owner | Jun 4, 2025 | Sale | −1,796 | $30.02 | $53.92K | 120,204 |
| Management Inc. Opaleye 10% owner | Jun 3, 2025 | Sale | −3,000 | $30.04 | $90.12K | 122,000 |
| Management Inc. Opaleye 10% owner | May 13, 2025 | Sale | −5,000 | $26.59 | $132.95K | 125,000 |
| Management Inc. Opaleye 10% owner | May 12, 2025 | Sale | −10,000 | $25.90 | $259.00K | 130,000 |
| John P. Saharek CEO & President, ImprimisRx | Apr 7, 2025 | Tax withholding | −109,475 | $23.09 | $2.53M | 467,388 |
| Andrew R. Boll Chief Financial Officer | Apr 7, 2025 | Tax withholding | −136,745 | $23.09 | $3.16M | 777,844 |
| Mark L. Baum Chief Executive Officer, Director, 10% owner | Apr 7, 2025 | Tax withholding | −300,363 | $23.09 | $6.94M | 2,599,462 |
| John P. Saharek CEO & President, ImprimisRx | Apr 3, 2025 | Option exercise | +277,200 | – | – | 576,863 |
| Andrew R. Boll Chief Financial Officer | Apr 3, 2025 | Option exercise | +346,500 | – | – | 914,589 |
| Mark L. Baum Chief Executive Officer, Director, 10% owner | Apr 3, 2025 | Option exercise | +762,300 | – | – | 2,899,825 |
| Management Inc. Opaleye 10% owner | Mar 24, 2025 | Sale | −5,000 | $30.01 | $150.05K | 140,000 |
| Management Inc. Opaleye 10% owner | Mar 18, 2025 | Sale | −5,000 | $29.64 | $148.20K | 145,000 |
| Management Inc. Opaleye 10% owner | Mar 18, 2025 | Sale | −5,000 | $30.01 | $150.05K | 140,000 |
| Management Inc. Opaleye 10% owner | Mar 18, 2025 | Sale | −5,000 | $29.64 | $148.20K | 145,000 |
| Management Inc. Opaleye 10% owner | Feb 28, 2025 | Sale | −5,000 | $28.05 | $140.25K | 150,000 |
| Management Inc. Opaleye 10% owner | Jan 22, 2025 | Sale | −20,000 | $35.59 | $711.80K | 155,000 |
| John P. Saharek CEO of ImprimisRx | Sep 11, 2024 | Tax withholding | −45,140 | $41.37 | $1.87M | 299,663 |
| John P. Saharek CEO of ImprimisRx | Sep 11, 2024 | Option exercise | +90,000 | $7.37 | $663.30K | 344,803 |
| Management Inc. Opaleye 10% owner | Apr 25, 2024 | Buy | +20,000 | $9.97 | $199.40K | 3,815,000 |
| Management Inc. Opaleye 10% owner | Apr 24, 2024 | Buy | +8,285 | $10.15 | $84.09K | 3,795,000 |
| Management Inc. Opaleye 10% owner | Apr 23, 2024 | Buy | +11,715 | $10.29 | $120.55K | 3,786,715 |
| Management Inc. Opaleye 10% owner | Apr 19, 2024 | Buy | +29,400 | $10.56 | $310.46K | 3,775,000 |
| Management Inc. Opaleye 10% owner | Mar 28, 2024 | Buy | +50,000 | $12.82 | $641.00K | 3,745,600 |
| Mark L. Baum CHIEF EXECUTIVE OFFICER, Director | Mar 22, 2024 | Buy | +9,000 | $11.59 | $104.31K | 2,137,525 |
| Management Inc. Opaleye 10% owner | Mar 20, 2024 | Buy | +50,600 | $9.65 | $488.29K | 3,695,600 |
| John P. Saharek CEO of ImprimisRx | Mar 1, 2024 | Option exercise | +5,000 | $8.75 | $43.75K | 254,803 |
| Andrew R. Boll CHIEF FINANCIAL OFFICER | Feb 20, 2024 | Option exercise | −18,480 | $10.67 | $197.18K | 568,089 |
| Andrew R. Boll CHIEF FINANCIAL OFFICER | Feb 20, 2024 | Option exercise | +45,000 | $10.67 | $480.15K | 586,569 |
| Mark L. Baum CHIEF EXECUTIVE OFFICER, Director | Feb 20, 2024 | Option exercise | +150,000 | $10.67 | $1.60M | 2,188,361 |
| Mark L. Baum CHIEF EXECUTIVE OFFICER, Director | Feb 20, 2024 | Option exercise | −59,836 | $10.67 | $638.45K | 2,128,525 |
| John P. Saharek CEO of ImprimisRx | Feb 20, 2024 | Option exercise | +30,000 | $10.67 | $320.10K | 262,419 |
| John P. Saharek CEO of ImprimisRx | Feb 20, 2024 | Option exercise | −12,616 | $10.67 | $134.61K | 249,803 |
| Andrew R. Boll CHIEF FINANCIAL OFFICER | Feb 7, 2024 | Option exercise | +7,400 | $7.71 | $57.05K | 541,569 |
| Mark L. Baum CHIEF EXECUTIVE OFFICER, Director | Feb 7, 2024 | Option exercise | +15,400 | $7.71 | $118.73K | 2,038,361 |
| Mark L. Baum Chief Executive Officer, Director | Nov 16, 2023 | Buy | +7,500 | $8.11 | $60.82K | 2,022,961 |
| Management Inc. Opaleye 10% owner | Nov 15, 2023 | Buy | +25,000 | $8.03 | $200.75K | 3,645,000 |
| John P. Saharek Chief Commercial Officer | Nov 10, 2023 | Tax withholding | −9,778 | $12.83 | $125.45K | 232,419 |
| John P. Saharek Chief Commercial Officer | Nov 10, 2023 | Option exercise | +20,000 | – | – | 242,197 |
| Management Inc. Opaleye 10% owner | Sep 20, 2023 | Buy | +5,983 | $14.49 | $86.69K | 3,620,000 |
| Management Inc. Opaleye 10% owner | Sep 19, 2023 | Buy | +14,017 | $14.65 | $205.35K | 3,614,017 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Harrow's stock actually held short. Settlement fails (shares not delivered on time) peaked at 72,090 shares on Oct 13, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Amir Shojaei CHIEF SCIENTIFIC OFFICER | Aug 21, 2026 | 11,250 | $450.00K | Aug 14, 2026 | OPTION EXERCISE |
See a number that looks wrong?